Xynomic Pharmaceuticals Holdings, a clinical stage US-China oncology drug development company, announced that Xynomic Research Institute (XRI) has successfully designed a series of potent RET kinase inhibitors by computer-assisted drug design.
GeneCentric Therapeutics announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs.
Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases, announced the successful completion of its $60m (£49.7m) Series B financing round.
Eidos Therapeutics has received a non-binding proposal dated August 8, 2019 (the Proposal) from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (BridgeBio), to purchase all of the outstanding common stock of the Company not already owned by BridgeBio.
Boehringer Ingelheim has forged a multi-year partnership with The University of Texas MD Anderson Cancer Center to carry out joint research towards rapid advancement of new therapies for various forms of cancers.
Jazz Pharmaceuticals has acquired US-based clinical-stage biotechnology company Cavion for a total potential consideration of $312.5m (£258.9m).
Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today the opening of its Clinical Development Shanghai Center, signalling the further expansion of R&D capability, especially in Oncology and Non-alcoholic steatohepatitis (NASH).
Bayer has agreed to acquire the remaining 50.2% interest in US-based biotechnology company BlueRock Therapeutics for around $240m (£197m) in cash.
Vesselon, an oncology therapeutics company, announced the acquisition of an FDA-approved drug Imagent.
An affiliate of investment firm Permira has agreed to acquire small molecule company Cambrex in a deal valued at around $2.4bn (£1.97bn), including its net debt.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.